Or
Contact UsCabazitaxel — brand name Jevtana. A taxane, but not the same story as docetaxel or paclitaxel. This one has a specific moment: prostate cancer that went through docetaxel and kept going anyway.
Why does it get considered? Resistance. Tumor cells that learned to eject docetaxel find cabazitaxel harder to deal with. The molecular structure does not fit the same export pumps as well. It stays inside the cell longer. This is not a stronger version of the previous drug — it is a different angle on a problem that the previous drug stopped solving.
It is not a light treatment. The bone marrow takes a significant hit. Fever plus very low white cells — what doctors call febrile neutropenia — is the risk that gets the most attention, and for good reason. Before the first infusion, blood counts, physical condition and the full treatment history all need to be on the table.
To divide, a cell has to physically pull itself apart. There is an internal scaffold that makes that possible. Cabazitaxel jams that scaffold. The cell stalls mid-division and cannot recover.
What makes it relevant after docetaxel is how cancer cells adapt. Over time, many prostate tumors develop mechanisms to pump taxanes out before they can do damage. Cabazitaxel was engineered to be a poor fit for those pumps — it gets pushed out less efficiently, stays inside the cell longer, does more damage before the cell can neutralise it.
That does not mean it works for every patient whose cancer moved through docetaxel. Tumor biology varies. But it is why cabazitaxel gets considered rather than repeating something that already stopped working.
Cabazitaxel occupies a narrow space in oncology. Not a drug that gets used across tumor types.
Prostate cancer is where its evidence sits. The clinical trials that established it focused on men whose disease moved through first-line chemotherapy. That is the context it was built for.
A few situations put it on the table.
Timing matters here more than with many drugs. Cabazitaxel competes with other agents that occupy the same treatment window. Whether it is the right choice at this particular moment depends on sequence — what came before, what is still available, and how the patient is holding up.
The team needs more than a diagnosis and a prior treatment list.
Neutrophil count at baseline shapes the entire plan. A patient who starts with already-compromised white cells faces a much steeper risk of serious infection. Growth factor support from cycle one — rather than waiting to see — is often the safer call.
Cabazitaxel goes in intravenously, usually every three weeks. Before each infusion, antihistamines, steroids and an H2 blocker go in first — not optional, not skippable.
Growth factor injections to support white cell recovery often run alongside it. Whether to use them from cycle one is decided before treatment starts, not after the first problem appears.
During treatment the team monitors:
A cycle delayed because neutrophils are too low is not a failure. It is the right call. Asking why the delay happened is always a reasonable question.
Cabazitaxel carries real toxicity. The blood count effects dominate the picture.
Febrile neutropenia cannot wait. Before cycle one every patient needs a number to call, knows what to say, and knows where to go if nobody picks up.
Some things need a call the same day, not the next appointment.
The gap between feeling roughly okay and a serious infection can close quickly when neutrophils are low. The team needs to be reachable and the patient needs to know how.
Post-docetaxel prostate cancer does not automatically mean cabazitaxel is next.
Cabazitaxel versus enzalutamide, abiraterone or radium-223 after docetaxel is not a simple ranking. What has already been given, how fast disease is moving, what the patient can tolerate — all of it feeds into the decision. No single right answer applies to everyone.
Cabazitaxel in prostate cancer is used as a single agent. What runs alongside it:
Adding other chemotherapy agents or experimental combinations outside clinical trials is not standard. More treatment is not automatically better, and with cabazitaxel’s toxicity profile, the bar for adding anything extra is high.
PSA shifts and imaging changes take cycles to assess. One data point after the first infusion is rarely enough to draw conclusions either way.
If disease is clearly moving through treatment, or side effects are crossing into unsafe, the plan needs to be reviewed. A second opinion is worth seeking when the options after docetaxel have not been fully laid out or when the reasoning behind cabazitaxel over other agents is not clear.
Tel Aviv Medical Clinic offers consultations and second opinions for patients with prostate cancer facing the post-docetaxel decision or already on cabazitaxel.
The consultation can cover:
We do not replace the treating doctor. We help the patient and family understand what the options actually are and arrive at the next conversation knowing what to ask.
Because the cancer that moved through docetaxel has already adapted to that mechanism. Switching to a random alternative often does not solve the problem. Cabazitaxel was built specifically for tumors that have developed the pumps used to eject docetaxel. It evades those pumps more effectively. That is not a guarantee it will work — tumor biology varies — but it is why it gets considered rather than simply trying something that has no particular advantage over what already failed.
Serious enough that we plan for it before cycle one, not after. Cabazitaxel can drop white cell counts significantly. If fever develops in that window, it needs assessment the same day — not monitoring at home overnight. I want every patient to have a number to call and to know exactly what to say when they use it. Growth factor support often starts from the first cycle rather than waiting to see what happens.
Fever plus very low white cells at the same time. White cells are the body’s infection defence. When they drop and fever appears, there is no normal buffer between the patient and whatever triggered it. Infections that a healthy immune system would handle easily can become dangerous fast. That is why it has its own emergency protocol and why I do not treat it as something to observe from home.
PSA over time, recent bone scan and CT, pathology from diagnosis, the full treatment list with dates — hormone therapies, docetaxel, everything else — and recent bloods. If there were significant side effects from previous treatment, write those down with rough timing. A clear picture of the treatment sequence so far is what makes the second opinion worth having.
That depends on the full history — what has already been given, in what order, and how the patient is doing now. Options after cabazitaxel in prostate cancer are limited and very individual. This is a conversation that needs the oncologist who knows the complete sequence. If that conversation has not happened yet, asking for it directly is reasonable.
This page gives general medical information. It is not a personal treatment plan. Cabazitaxel should be discussed only after full review of treatment history, blood counts, performance status, liver function and overall condition.
Do not start, stop or change chemotherapy without your treating oncologist.
For consultation about Cabazitaxel treatment:
📞 +972-73-374-6844
📧 [email protected]
💬 WhatsApp: +972-52-337-3108
